Intensity Therapeutics (INTS) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 16, 2026, to be held virtually for shareholder participation.

• Shareholders are encouraged to review proxy materials and vote by June 15, 2026.

Voting matters and shareholder proposals

• Election of two Class III directors, Dr. Emer Leahy and Lewis H. Bender, for three-year terms expiring in 2029.

• Ratification of EisnerAmper LLP as independent auditor for fiscal year ending December 31, 2026.

• Amendment to the 2021 Stock Incentive Plan to increase authorized shares by 150,000.

• Amendment to the 2024 Employee Stock Purchase Plan to increase available shares by 25,000.

• Approval to adjourn or postpone the meeting if necessary to solicit additional proxies or establish a quorum.

Board of directors and corporate governance

• Board recommends voting in favor of all proposals, including director elections and plan amendments.